Inhibition of XLF-mediated NHEJ activity results in chemosensitization in a HCC xenograft model, suggesting that XLF is a novel candidate for the development of new DNA repair inhibitors for combination therapy. Here, NHEJ1 is linked to hepatocellular carcinoma.